Gyre Therapeutics, Inc. (GYRE) Operating margin 2017–2025
Gyre Therapeutics, Inc. (GYRE) operating margin by fiscal year — reported operating income divided by reported revenue.
9.9%FY2025 · since FY2017: -2143.6% → 9.9%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2025 | 9.9% | -5.4 pp |
| FY2024 | 15.3% | +74.5 pp |
| FY2023 | -59.3% | -68.3 pp |
| FY2022 | 9.0% | +1206.8 pp |
| FY2021 | -1197.8% | -923.9 pp |
| FY2020 | -273.9% | — |
| FY2018 | -563700.0% | -561556.4 pp |
| FY2017 | -2143.6% | — |
Operating margin = reported operating income ÷ reported revenue for the same fiscal year. Operating-loss years show as a negative margin.
Source: SEC XBRL filings · For reference only · Not investment advice
More GYRE financial trends
GYRE RevenueGYRE Net incomeGYRE Net marginGYRE Gross profitGYRE Gross marginGYRE Operating incomeGYRE Operating cash flowGYRE Free cash flowGYRE Capital expendituresGYRE Return on equityGYRE Stock buybacksGYRE Dividends paidGYRE Total assetsGYRE Total liabilitiesGYRE Shareholders’ equityGYRE overview →